Drugs

Article	Citations
Correction: New Pharmacologic Approaches to the Treatment of Bipolar Depression	463
Correction: Targeting KRASG12C in Non-Small-Cell Lung Cancer: Current Standards and Developments	452
Suprachoroidal Space Triamcinolone Acetonide: A Review in Uveitic Macular Edema	339
Alcohol-Associated Liver Disease: Evolving Concepts and Treatments	324
Eftrenonacog Alfa: A Review in Haemophilia B	231
Comment on “Recent Human Papillomavirus Vaccination is Associated with a Lower Risk of COVID-19: A US Database Cohort Study”	197
Teclistamab: First Approval	170
New Therapies on the Horizon for Primary Biliary Cholangitis	149
Analysis of Cerebrospinal Fluid, Plasma β-Amyloid Biomarkers, and Cognition from a 2-Year Phase 2 Trial Evaluating Oral ALZ-801/Valiltramiprosate in APOE4 Carriers with Early Alzheimer’s Disease Using	147
Spesolimab for the Treatment of Generalized Pustular Psoriasis	131
Bimekizumab for the Treatment of Psoriasis	129
Targeting DNA Damage Response Deficiency in Thoracic Cancers	129
Authors’ Reply to Toda: Multimodal Multidisciplinary Management of Patients with Moderate to Severe Pain in Knee Osteoarthritis: A Need to Meet Patient Expectations	126
Senaparib: First Approval	120
Vorasidenib: First Approval	115
Epcoritamab: First Approval	114
Asthma and Cardiovascular Diseases: Navigating Mutual Pharmacological Interferences	110
Aprocitentan: First Approval	108
Influenza Vaccine Effectiveness and Progress Towards a Universal Influenza Vaccine	107
Cosibelimab: First Approval	107
Lenacapavir: First Approval	101
Emerging Therapies for Chronic Hepatitis B and the Potential for a Functional Cure	96
Safety of Anti-osteoarthritis Medications: A Systematic Literature Review of Post-marketing Surveillance Studies	96
Androgenetic Alopecia: Therapy Update	96
Acoltremon: First Approval	95

Efficacy and Safety of Plecanatide in Chinese Patients with Functional Constipation: A Phase III Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial	94
QT Prolongation and Risk of Death with the Use of Methadone for Chronic Cancer and Noncancer Pain: Myths or Reality?	94
Olipudase Alfa: First Approval	90
Ivarmacitinib Sulfate: First Approval	86
Drugs in Development to Manage Acute Pain	85
Atogepant: First Approval	85
Repotrectinib: First Approval	84
Finerenone: First Approval	83
Danicopan: First Approval	83
Efficacy and Safety of CDK4/6 Inhibitors: A Focus on HR+/HER2− Early Breast Cancer	83
Correction to: Ofatumumab: A Review in Relapsing Forms of Multiple Sclerosis	83
Relugolix/Estradiol/Norethisterone (Norethindrone) Acetate: A Review in Symptomatic Uterine Fibroids	81
SER-109 (VOWST™): A Review in the Prevention of Recurrent Clostridioides difficile Infection	79
Delgocitinib 20 mg/g Cream: A Review in Chronic Hand Eczema	77
Treatment of Cryptococcal Meningitis: How Have We Got Here and Where are We Going?	76
Cancer Pain Treatment Strategies in Patients with Cancer	75
Novel Drugs for the Treatment of Pulmonary Arterial Hypertension: Where Are We Going?	75
Olverembatinib: First Approval	75
Alzheimer’s Disease: Novel Targets and Investigational Drugs for Disease Modification	74
Mosunetuzumab: First Approval	71
Correction to: Cefiderocol: A Review in Serious Gram-Negative Bacterial Infections	70
Aligning Large Language Models with Humans: A Comprehensive Survey of ChatGPT’s Aptitude in Pharmacology	69
Correction to: Tapinarof Cream 1%: First Approval	68
Correction to: Fenfluramine: A Review in Dravet and Lennox-Gastaut Syndromes	68
Drugs Targeting Cough Receptors: New Therapeutic Options in Refractory or Unexplained Chronic Cough	67
Pharmacological Treatments of Temporomandibular Disorders: A Systematic Review Including a Network Meta-Analysis	66
Situational Prevention of Migraine Attacks: Can Early Treatment Change the Conversation?	65
Correction to: Prevention and Treatment of Monkeypox	64
PARP Inhibition, a New Therapeutic Avenue in Patients with Prostate Cancer	64
Pozelimab: First Approval	61
Managing Burning Mouth Syndrome: Current and Future Directions	61
Treatment of Ovarian Cancer Beyond PARP Inhibition: Current and Future Options	60
Targeting Interferon Signalling in Systemic Lupus Erythematosus: Lessons Learned	60
The Place of Cannabinoids in the Treatment of Gynecological Pain	58
Overview of DaxibotulinumtoxinA for Injection: A Novel Formulation of Botulinum Toxin Type A	56
Tovorafenib: First Approval	56
Correction to: Concizumab: First Approval	55
Dorzagliatin: First Approval	55
The Utilization of the Accelerated Approval Pathway in Oncology: A Case Study of Pembrolizumab	55
Current Management of Peripheral Artery Disease: Focus on Pharmacotherapy	55
Sunvozertinib: First Approval	55
Might It Be Appropriate to Anticipate the Use of Long-Acting Muscarinic Antagonists in Asthma?	54
Correction: From Prospective Evaluation to Practice: Model-Informed Dose Optimization in Oncology	54
Correction to: Remdesivir: A Review in COVID-19	54
Recent Human Papillomavirus Vaccination is Associated with a Lower Risk of COVID-19: A US Database Cohort Study	53
Asciminib: First Approval	52
Paracetamol Combination Therapy for Back Pain and Osteoarthritis: A Systematic Review and Meta-Analyses	52
Disitamab Vedotin: First Approval	52
Pharmacotherapy for Dravet Syndrome: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials	51
Catumaxomab: First Approval	51

Ozoralizumab: First Approval	51
Givinostat: First Approval	50
Effects of Oral ALZ-801/Valiltramiprosate on Plasma Biomarkers, Brain Hippocampal Volume, and Cognition: Results of 2-Year Single-Arm, Open-Label, Phase 2 Trial in APOE4 Carriers with Early Alzheimer’	50
Focus on Metformin: Its Role and Safety in Pregnancy and Beyond	50
Fluvoxamine for the Early Treatment of SARS-CoV-2 Infection: A Review of Current Evidence	50
Tirzepatide: A Review in Type 2 Diabetes	49
Gepirone Extended-Release: First Approval	49
Aumolertinib: A Review in Non-Small Cell Lung Cancer	49
Birch Bark Extract: A Review in Epidermolysis Bullosa	48
Correction to: Sotorasib: First Approval	47
Correction: Teprotumumab: A Review in Thyroid Eye Disease	47
Atrasentan: First Approval	45
Futibatinib: First Approval	45
Ensitrelvir Fumaric Acid: First Approval	44
Correction to: Efmoroctocog Alfa: A Review in Haemophilia A	44
Omalizumab in Severe Asthma: Effect on Oral Corticosteroid Exposure and Remodeling. A Randomized Open-Label Parallel Study	44
Avacincaptad Pegol: First Approval	44
Current Understanding of Complement Proteins as Therapeutic Targets for the Treatment of Immunoglobulin A Nephropathy	43
Tisotumab Vedotin: First Approval	42
Mitapivat: A Review in Pyruvate Kinase Deficiency in Adults	41
Fezolinetant: First Approval	41
Update on Mpox Management: Epidemiology, Vaccines and Therapeutics, and Regulatory Changes	41
Treatment of Non-Infectious Corneal Injury: Review of Diagnostic Agents, Therapeutic Medications, and Future Targets	41
Spondyloarthropathy in Inflammatory Bowel Disease: From Pathophysiology to Pharmacological Targets	39
Eye Involvement and Management in Inherited Epidermolysis Bullosa	39
Advanced-Stage Chronic Myeloid Leukemia: Options for Difficult Treatment Situations	39
Zastaprazan: First Approval	39
Imeglimin Hydrochloride: First Approval	38
Managing Pain in Fibromyalgia: Current and Future Options	38
Effectiveness of Interventions to Reduce Opioid Use After Orthopaedic Surgery: A Systematic Review of Randomised Controlled Trials	38
Gastrointestinal Dysfunction in Parkinson’s Disease	37
Daratumumab: A Review in Newly Diagnosed Systemic Light Chain Amyloidosis	37
Global Consumption Trend of Antifungal Agents in Humans From 2008 to 2018: Data From 65 Middle- and High-Income Countries	37
Lotilaner Ophthalmic Solution 0.25%: First Approval	37
Imetelstat: First Approval	37
Correction: Lumasiran: A Review in Primary Hyperoxaluria Type 1	37
Tamoxifen Dose De-Escalation: An Effective Strategy for Reducing Adverse Effects?	36
Recent United States Developments in the Pharmacological Treatment of Dry Eye Disease	35
Correction: Iptacopan: First Approval	35
Beremagene Geperpavec: First Approval	35
Varenicline Solution Nasal Spray: A Review in Dry Eye Disease	34
Safety of Janus Kinase Inhibitors in Inflammatory Bowel Diseases	34
Tebentafusp: First Approval	34
The Antifungal Pipeline: Fosmanogepix, Ibrexafungerp, Olorofim, Opelconazole, and Rezafungin	33
Acknowledgement to Referees	33
Remdesivir Discontinuation Decisions Based on Thresholds of Aminotransferase in an Observational Registry	33
Correction to: Pharmacological Approaches to Managing Violence and Aggression in Prison Populations: Clinical and Ethical Issues	33
Crinecerfont: First Approval	32
Efficiency and Safety of Noninvasive and Intravesical Therapy for Adult Neurogenic Lower Urinary Tract Dysfunction: A Systematic Review and Network Meta-analysis of Randomized Controlled Trials	31
Revumenib: First Approval	31
Authors’ Reply to Mazza et al.: “Fluvoxamine for the Early Treatment of SARS‑CoV‑2 Infection: A Review of Current Evidence”	31
Mavorixafor: First Approval	30
Diagnosis and Treatment of AL Amyloidosis	30
Botulinum Toxin-A for the Treatment of Myogenous Temporomandibular Disorders: An Umbrella Review of Systematic Reviews	30
Retifanlimab: First Approval	30
Revolutionary Changes in the Management of Lupus Nephritis: Towards De-Glucocorticoid or No-Glucocorticoid	30
Nogapendekin alfa Inbakicept: First Approval	30
Donafenib: First Approval	30
Avatrombopag: A Review in Thrombocytopenia	29
Immune Mechanisms in Epileptogenesis: Update on Diagnosis and Treatment of Autoimmune Epilepsy Syndromes	29
Targeting the Sphingosine-1-Phosphate Pathway: New Opportunities in Inflammatory Bowel Disease Management	29
The Epidemiology and Pathogenesis and Treatment of Pseudomonas aeruginosa Infections: An Update	28
Rationale and Clinical Use of Bronchodilators in Adults with Bronchiectasis	28
Comment on: “Risk of Erectile Dysfunction in Male Patients with Gout Treated with Febuxostat or Allopurinol: A Propensity Score-Matched Cohort Study”	28
Correction to: Sparsentan: First Approval	28
Correction: Zastaprazan: First Approval	28
Correction to: Abrocitinib: First Approval	28
Correction to: REal worlD Effectiveness and Safety of Mepolizumab in a Multicentric Spanish Cohort of Asthma Patients Stratified by Eosinophils: The REDES Study	28
Direct-Acting Antivirals and the Risk of Arrhythmias and Conduction Disorders in Patients with Chronic Hepatitis C: A French Nationwide Cohort Study	28
Daridorexant: First Approval	27
Gabapentinoids for Pain: A Review of Published Comparative Effectiveness Trials and Data Submitted to the FDA for Approval	27
Correction to: Spesolimab: First Approval	27
Ravulizumab: A Review in Generalised Myasthenia Gravis	27
Efficacy and Safety of Sovateltide in Patients with Acute Cerebral Ischaemic Stroke: A Randomised, Double-Blind, Placebo-Controlled, Multicentre, Phase III Clinical Trial	27
Moderate-Intensity Statin Plus Ezetimibe: Time to Rethink it as an Optimal Initial Lipid-Lowering Strategy	26
Methadone for Cancer Pain Management in Children: A Review of Literature	26
Combination of PARP Inhibitors and Androgen Receptor Pathway Inhibitors in Metastatic Castration-Resistant Prostate Cancer	26
Remdesivir: A Review in COVID-19	26
Antibacterials with Novel Chemical Scaffolds in Clinical Development	26
Recent Clinical Trials Insights into the Treatment of Primary Membranous Nephropathy	26

Keverprazan Hydrochloride: First Approval	26
Zolbetuximab: First Approval	26
A Review of RRx-001: A Late-Stage Multi-Indication Inhibitor of NLRP3 Activation and Chronic Inflammation	25
Marstacimab: First Approval	25
Ripretinib: A Review in Gastrointestinal Stromal Tumours as Fourth-or Later-Line of Therapy	25
Publisher Correction: Efficacy and Safety of RBX2660 in PUNCH CD3, a Phase III, Randomized, Double-Blind, Placebo-Controlled Trial with a Bayesian Primary Analysis for the Prevention of Recurrent Clos	25
Safety, Immunogenicity and Interchangeability of Biosimilar Monoclonal Antibodies and Fusion Proteins: A Regulatory Perspective	25
Gefapixant: First Approval	25